Yuan Dong, Ted...The siege surged by 300% injections! Osaikon is here too

Recently, Jiangsu Aosaikang Pharmaceutical has entered the administrative examination and approval stage with the imitation of Paricalcitol injection in Category 6 and is expected to be approved in the near future.

Data show that paricalcitol is the latest generation of selective vitamin D receptor agonists, which can effectively reduce parathyroid hormone (PTH) in combination with vitamin D receptors, and is used to treat chronic renal failure patients undergoing hemodialysis.

Sales of Paricalcitol Injections in Public Medical Institutions in China in Recent Years

Source: Terminal competition landscape of China's public medical institutions

Paricalcitol injection was developed by AbbVie and was approved for marketing by the FDA in 1998.

Source: MED2.

In recent years, with the efforts of domestic pharmaceutical companies, AbbVie's paricalcitol injection market share has declined rapidly, from its monopoly in 2017 to less than 20% in the first half of 2020.

Source: Mi Nei Net database